Retro Biosciences, a startup focused on longevity research, has achieved a valuation of $1.8 billion following its recent fundraising efforts. This financial milestone underscores the growing interest and investment in the field of healthspan extension.
The company aims to develop innovative therapies that target aging and improve overall health. With the new funding, Retro Biosciences plans to accelerate its research and development initiatives.
This valuation reflects a significant commitment from investors to support advancements in longevity science, highlighting the potential market for solutions aimed at extending healthy lifespan.